Erasca (ERAS) Research & Development (2020 - 2026)
Erasca posted quarterly Research & Development of $27.3 million for Q1 2026, up 4.99% year-on-year from $26.0 million in Q1 2025, and up 17.31% on a QoQ basis from $23.2 million in Q4 2025.
Erasca (ERAS) has 7 years of Research & Development data on file, last reported at $27.3 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 4.99% year-over-year to $27.3 million; the trailing twelve-month figure through Mar 2026 stood at $94.1 million (down 16.5% YoY), and the FY2025 full-year result was $92.9 million, down 19.51% from the prior year.
- Research & Development for Q1 2026 stood at $27.3 million, up from $23.2 million in the prior quarter.
- Across five years, Research & Development topped out at $33.0 million in Q2 2024 and bottomed at $21.2 million in Q2 2025.
- The 5-year median for Research & Development is $27.3 million (2026), against an average of $26.6 million.
- The widest annual swing landed in 2022, when Research & Development jumped 124.0%; it then slumped 35.91% in 2025.
- A 5-year view of Research & Development shows it stood at $29.4 million in 2022, then fell by 15.5% to $24.8 million in 2023, then advanced by 5.31% to $26.1 million in 2024, then retreated by 11.03% to $23.2 million in 2025, then increased by 17.31% to $27.3 million in 2026.
- The last three Research & Development figures came in at $27.3 million (Q1 2026), $23.2 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 27.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.27 Mn |
| Dec 31, 2025 | 23.24 Mn |
| Sep 30, 2025 | 22.47 Mn |
| Jun 30, 2025 | 21.17 Mn |
| Mar 31, 2025 | 25.97 Mn |
| Dec 31, 2024 | 26.12 Mn |
| Sep 30, 2024 | 27.63 Mn |
| Jun 30, 2024 | 33.03 Mn |
| Mar 31, 2024 | 28.57 Mn |
| Dec 31, 2023 | 24.81 Mn |
| Sep 30, 2023 | 25.21 Mn |
| Jun 30, 2023 | 26.22 Mn |
| Mar 31, 2023 | 27.59 Mn |
| Dec 31, 2022 | 29.36 Mn |
| Sep 30, 2022 | 28.18 Mn |
| Jun 30, 2022 | 27.49 Mn |
| Mar 31, 2022 | 27.43 Mn |
| Dec 31, 2021 | 24.13 Mn |
| Sep 30, 2021 | 19.95 Mn |
| Jun 30, 2021 | 17.60 Mn |
| Mar 31, 2021 | 12.25 Mn |
| Dec 31, 2020 | 10.07 Mn |
| Sep 30, 2020 | 9.07 Mn |
| Jun 30, 2020 | 5.86 Mn |